This Week’s Biopharma News: Texas Takes on BMS and Sanofi
November 26, 2025
-
7 min
5 Key Takeaways
-
1
Texas is suing pharmaceutical companies over Plavix marketing practices.
-
2
Allegations cite deceptive practices and knowledge of reduced efficacy.
-
3
FDA approved Keytruda and Padcev for bladder cancer.
-
4
Itvisma approved for spinal muscular atrophy in older patients.
-
5
Posdinemab study in Alzheimer's disease was discontinued for lack of efficacy.
The State of Texas is suing Bristol-Myers Squibb and Sanofi for alleged deceptive marketing practices surrounding Plavix, an antiplatelet medication that may be ineffective for certain populations due to genetic factors. The lawsuit cites the companies' knowledge of Plavix's reduced efficacy since the 1990s, particularly among Black, East Asian, and Pacific Islander individuals, and claims this led to improper prescriptions and increased patient risks, prompting calls for civil penalties and restitution. In other news, the FDA approved Keytruda and Padcev for bladder cancer treatment and Itvisma for spinal muscular atrophy.
Listen Tab content
